Products
Platform
Research
Market
Learn
Partner
Support
IPO

K

Krishna Institute of Medical Sciences Share Price

629.85
-10.95 (-1.71%)
KIMS • 24 Dec, 2025 | 03:29 PM
Buywith MTF at 3.33x leverage

1Y Annualised Return

7.00%

3Y Annualised Return

28.39%

The current prices are delayed, login or Open Demat Account for live prices.

Krishna Institute of Medical Sciences Stock Performance

1W Return-2.39
1Y Return5.17
Today's Low627
Prev. Close640.80
Mkt Cap (Cr.)25,202.75
1M Return-7.16
3Y Return113.66
52-Week High798.4
Open641.00
PE Ratio88.70
6M Return0.48
Today's High642.65
52-Week Low474.05
Face Value2

Krishna Institute of Medical Sciences Company background

Founded in: 1973
Krishna Institute of Medical Sciences Limited (KIMS) was erstwhile incorporated as Jagjit Singh and Sons Private Limited, a Private Limited Company on July 26, 1973 in Mumbai. Subsequently, the name of the Company changed to Krishna Institute of Medical Sciences Private Limited on January 2, 2004 and further upon its conversion to a Public Company, the name was changed to Krishna Institute of Medical Sciences Limited on January 29, 2004. The Company is one of the largest corporate groups in India, with hospitals in Telangana, Andhra Pradesh Maharashtra providing multidisciplinary integrated services with a focus on tertiary and quaternary healthcare at affordable cost. It is engaged in rendering medical and healthcare services. It operate 12 multispecialty hospitals under the KIMS Hospitals brand, with an aggregate capacity of over 5000 beds. It offer a comprehensive range of healthcare services in over 40 specialties and super specialties, including cardiac sciences, oncology, neurosciences, gastric sciences, orthopaedics, organ transplantation, renal sciences and mother child care.Until the year 2003, the Company was owned, managed and controlled by Jagjit Singh and certain of his family members, who together owned the entire shareholding of the Company. In February 2003, acting in pursuance of the Takeover MoU, certain of its Promoters, namely Dr. Bhaskar Rao Bollineni, Krishnaiah Bollineni and BRMH, along with certain other individuals and entities, acquired the entire equity share capital of the Company.Led by Dr. Bhaskar Rao Bollineni, Managing Director and CEO of the Company, a renowned cardiothoracic surgeon, it has grown from a single hospital to a chain of multispecialty hospitals, both organically and through strategic acquisitions. The oldest hospital in their network was established in 2000 at Nellore, by its Corporate Promoter, BRMH, with a capacity of approximately 200 beds and, At present, the hospital network has grown to six multispecialty hospitals in six cities, with a total capacity of 4000 beds, including 1,705 operational beds. The Hospitals are equipped with stateoftheart medical equipment and employ practices and policies which help to provide quality healthcare services to their patients. It was one of the first hospitals in Hyderabad to install 4Arm HD da Vinci Robot technology at Secunderabad hospital. The flagship hospitals at Secunderabad and Rajahmundry have been accredited by the National Accreditation Board for Hospitals and Healthcare Providers, India (NABH). The Hospital at Secunderabad is accredited with ISO 9001:2008 certification and has also been accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL). The Hospital situated at Secunderabad was awarded the Healthcare Excellence Award, by the Indo Global Healthcare Summit and Expo, in 2015. It has also received awards from the Association of Healthcare Providers (India) (AHPI) for nursing excellence, in 2015 and for Patient Friendly Hospital, in 2017. In 2017, it was awarded the best hospital of the year in the multispecialty hospital category in Hyderabad by Times Healthcare Achievers Awards and in 2016 received the Pharmacie DeQualite certification from Bureau Veritas. Further, it was the first hospital in Andhra Pradesh and Telangana to have been Green OT certified in 2016. It is also the laureate of the Asia Pacific Society of Infection Control CSSD Center of Excellence Silver Award 20152016. Neurology India Journal has ranked the neurology department at its hospital at Secunderabad as the third biggest centre in India on the basis of volume of epilepsy surgeries performed, as on July 31, 2016.In addition to healthcare services, the company also conduct medical education programmes through its affiliations with state medical boards and universities, for various broad and super specialties at its hospitals in Secunderabad and Rajahmundry, including for DNB, under graduation, postgraduation, PhD and diploma programmes. It is also affiliated with Kaloji Narayana Rao University of Health Sciences and the Andhra Pradesh Para Medical Board.During 2022, Sunshine Hospitals became subsidiary of the Company effective from April, 2022. In 202223, the Company opened an exclusive Gastroenterology unit at Vizag. During FY 202223, Sarvejana Healthcare Private Limited became a Subsidiary of the Company effective 01st April 2022 SPANV Medisearch Lifesciences Private Limited became the Subsidiary of Company on 01.09.2022. Suryateja Healthcare Private Limited has ceased to be step down subsidiary of the Company w.e.f. December 01, 2022.The Nagpur Hospital became functional in 2024. The Company acquired a running hospital of 200 bedsQUEENS NRI HOSPITAL in Vizag, Andhra Pradesh in Jul24.The Company opened two units at Kannur and Kollam in Kerala in FY25. The first liver transplantation in Rayalaseema region in Andhra Pradesh took place in KIMS hospitals at Kurnool. Similarly, another liver transplantation took place at KIMS in Srikakulam in 2025. Company launched a 300bed facility in Thane, Mumbai in April 2025. Company operationalised fullfledged units in Nashik and Sangli (Maharashtra), Kannur and Kollam (Kerala) and Guntur (Andhra Pradesh). It launched the second unit, at Seethammadhara, with a fertility centre, Paediatric and Childcare unit under the Cuddles brand and a specialty care centre. It introduced a foot care clinic and a rehabilitation facility in Hyderabad.

Krishna Institute of Medical Sciences Financial Highlights


For the full year FY2025–2026, revenue reached ₹3067 crore and profit touched at ₹404 crore. As of Sep '25, Krishna Institute of Medical Sciences’s market capitalisation stood at ₹25,202.75 crores. Shareholding as of Sep '25 shows promoters holding 34.1%, with FIIs at 15%, DIIs at 32.2%, and public at 18.7%.

Krishna Institute of Medical Sciences Share Price Today


As of 24 Dec 2025, Krishna Institute of Medical Sciences share price is ₹629.8. The stock opened at ₹641 and had closed at ₹640.8 the previous day. During today’s trading session, Krishna Institute of Medical Sciences share price moved between ₹627.00 and ₹642.65, with an average price for the day of ₹634.83. Over the last 52 weeks, the stock has recorded a low of ₹474.05 and a high of ₹798.40. In terms of performance, Krishna Institute of Medical Sciences share price has increased by 1% over the past six months and has increased by 7.00% over the last year.
Read More
Krishna Institute of Medical Sciences SIP Return Calculator
5,000
Over the past
Total Investment of ₹0
Monthly SIP of 5,000 would have become 0 in 3 years with a gain of 0 (+0.00%)
View details of Market Depth

Krishna Institute of Medical Sciences Fundamental

Market Cap (in crs)

25,202.75

Face Value

2

Turnover (in lacs)

4,518.39

Key Metrics

Qtr Change %
32.87% Gain from 52W Low
-14.5
Dividend yield 1yr %
0

Krishna Institute of Medical Sciences Key Financials

View more
Loading chart...
Krishna Institute of Medical Sciences Quarterly Revenue
Krishna Institute of Medical Sciences Yearly Revenue
Krishna Institute of Medical Sciences Quarterly Net Profit/Loss
Krishna Institute of Medical Sciences Yearly Net Profit/Loss

Krishna Institute of Medical Sciences Result Highlights

  • Krishna Institute of Medical Sciences Ltd reported a 9.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 23.3%.

  • Its expenses for the quarter were up by 13.4% QoQ and 39.9% YoY.

  • The net profit decreased 15.3% QoQ and decreased 40.3% YoY.

  • The earnings per share (EPS) of Krishna Institute of Medical Sciences Ltd stood at 1.67 during Q2 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Krishna Institute of Medical Sciences Shareholding Pattern

Promoter
34.1%
Foreign Institutions
15%
Mutual Funds
26.7%
Domestic Institutions
32.2%
Public
18.7%

Krishna Institute of Medical Sciences Technical Analysis

Moving Averages Analysis
629.85
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
Day EMA5
639.10
Day EMA10
647.90
Day EMA12
651.00
Day EMA20
660.70
Day EMA26
666.30
Day EMA50
681.80
Day EMA100
691.30
Day EMA200
672.40
Delivery & Volume
Loading chart...

Day

84.30%

Week

65.60%

Month

65.40%

Delivery & Volume

633.17
Pivot
Resistance
First Resistance
639.33
Second Resistance
648.82
Third Resistance
654.98
Support
First Support
623.68
Second support
617.52
Third Support
608.03
Relative Strength Index
31.55
Money Flow Index
26.65
MACD
-15.31
MACD Signal
-12.14
Average True Range
17.62
Average Directional Index
22.78
Rate of Change (21)
-6.71
Rate of Change (125)
-3.43
Compare

Krishna Institute of Medical Sciences Latest News

21 DEC 2025 | Sunday
19 DEC 2025 | Friday
15 DEC 2025 | Monday

Please be aware that Krishna Institute of Medical Sciences stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account